Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00161226 · ClinicalTrials.gov registry record

A Randomized, Controlled, Comparative Study of a Levonorgestrel Intrauterine System for the Prevention of Endometrial Cancer in Patients Aged 40-50 With BMI Greater Than 35

A clinical trial, sponsored by University of Medicine and Dentistry of New Jersey.

Terminated
Registry status
44
Enrollment target

NCT00161226: Clinical Trial study, sponsored by University of Medicine and Dentistry of New Jersey.

NCT00161226 is a clinical trial that was terminated before completion, run by University of Medicine and Dentistry of New Jersey. The registered enrollment target is 44 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00161226 was terminated before completion, sponsored by University of Medicine and Dentistry of New Jersey.

TERMINATED
Registry status
44 participants
Enrollment target

Study Summary

Endometrial (uterine) cancer affects over 40,000 women each year in the United States. At this time there are no medications to prevent endometrial cancer. Women who are heavy are at increased risk of this cancer. Progestins have been used to treat endometrial hyperplasia and cancer in women who wanted to retain their fertility or who were not surgical candidates. Oral progestins are associated with side effects such as weight gain, mood changes, headaches, and acne. A device called Mirena has a type of progesterone in it. Because it is placed directly in the uterus it can give a powerful amount of progestin with less side effects. In this project, we will enroll 44 women who are aged 40-50 and who have a body mass index (BMI) greater than 40. (BMI is a measure of obesity. Normal is less than 25.) They will be randomized to either observation or treatment. The women in the treatment group will have a levonorgestrel intrauterine system (Mirena, LNG-IUS) placed for one year. All of the women will have endometrial biopsies and blood work at the beginning and end of the study. All of the women will have an ultrasound at the beginning of the study. The information will then be used to assess whether or not the LNG-IUS will be an effective prevention agent. The women will be contacted once a year for 5 years to see if they have had endometrial hyperplasia or cancer. A special lab study called microarray will be used to see what genes are turned on or off in the uterine lining.

Interventions

  • DEVICE Levonorgestrel intrauterine system

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2004-02
Est. Completion 2006-06

Why NCT00161226 stopped before completion

NCT00161226 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 44 participants, a relatively small participant target.

The record links to 0 conditions, and to 1 intervention - of which Levonorgestrel intrauterine system is the first listed.

NCT00161226 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00161226 about?

NCT00161226 is a clinical study titled "A Randomized, Controlled, Comparative Study of a Levonorgestrel Intrauterine System for the Prevention of Endometrial Cancer in Patients Aged 40-50 With BMI Greater Than 35". Endometrial (uterine) cancer affects over 40,000 women each year in the United States. At this time there are no medications to prevent endometrial cancer. Women who are heavy are at increased risk of this cancer. Progestins have been used to treat endometrial hyperplasia and cancer in women who wan...

What is the current status of trial NCT00161226?

This trial is currently terminated. The enrollment target is 44 participants. The study started on 2004-02. Estimated completion is 2006-06.

What interventions are being tested in trial NCT00161226?

The interventions under investigation include: Levonorgestrel intrauterine system (DEVICE).

Who is sponsoring clinical trial NCT00161226?

This trial is sponsored by University of Medicine and Dentistry of New Jersey, which has 88 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02323945 · 44 participants · NA

    Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury

  • NCT03093909 · 44 participants · Phase 1

    Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

  • NCT03104491 · 44 participants · Phase 1

    Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

  • NCT03781765 · 44 participants · Phase 4

    Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00161226, the US trial registry maintained by the National Library of Medicine. NCT00161226 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.